| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Fexlamose | MUC-031; AER-01 | Phase 2 Clinical | Trinity College Dublin, University College Dublin, University Of California San Francisco | Cystic Fibrosis; Lung Diseases; Pulmonary Disease, Chronic Obstructive | Details |
| NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology) | Phase 2 Clinical | Chongqing Sidemu Biotechnology Technology Co Ltd | Coronavirus Disease 2019 (COVID-19); Hematologic Neoplasms | Details | |
| HH-120 | HH-120 | Phase 2 Clinical | Huahui Health Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| SBK-001 | SBK-001 | Phase 2 Clinical | Chengdu Shibeikang Biomedical Technology Co Ltd | Acute Lung Injury; Respiratory Tract Diseases | Details |
| 68Ga-labeled ACE2 Targeting Probe(Peking Union Medical College Hospital) | 68Ga-A3 | Phase 1 Clinical | Peking Union Medical College Hospital | Lung Neoplasms | Details |
| AOD01 | AOD01; AOD-01 | Phase 1 Clinical | A*Star | Coronavirus Disease 2019 (COVID-19) | Details |
| 68Ga-DX600 | Clinical | Beijing Cancer Hospital | Solid tumours | Details |





